Recent Interviews

Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".

Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".

John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)


Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"

14. September 2021 | 12:02 CET

MorphoSys, HelloFresh, Aspermont - Price halving or rebound?

  • Investments
Photo credits:

Investors are likely to speculate on a rebound in the Valneva share in the coming days; because the price slide of over 30% on Monday was violent. Stifel analysts see sales and earnings estimates for 2020 and 2021 in jeopardy after the UK government unexpectedly canceled a major order for the COVID-19 vaccine under development. Investors have been waiting for a rebound in MorphoSys shares for some time. The latest analyst assessment gives little hope. If Bernstein Research has its way, HelloFresh could soon be down almost 50%. Aspermont seems ripe for a rebound - the share is interesting from a chart perspective, and analysts advise buying.

time to read: 3 minutes by Fabian Lorenz



Fabian Lorenz

For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

About the author

Aspermont: Ripe for a price increase in the short and long term

Investors can speculate on a rebound in Aspermont Limited. The share of one of the world's leading providers of business-to-business (B2B) media for the commodities sector has slipped in recent days to the lower end of a sideways movement between AUD 0.022 and AUD 0.032, which has been stable for months. With a continuation of the trend, a good 30% price potential beckons. In the long term, even more, is possible. Thus, the German research house GBC analysts recommend the share of the Australian technology enterprise to the purchase ( The price target is AUD 0.09. Aspermont publishes subscription-based content services for the mining, energy, agriculture and technology sectors worldwide. In business-to-business marketing, the Company is one of the leading players globally, GBC said. In fiscal 2020, Aspermont successfully completed its turnaround with positive EBITDA, it said. The Company is debt-free and has AUD 7.3 million in cash and cash equivalents.

A new growth phase is now beginning for Aspermont, with 7.4 million contacts and a new lead generation program expected to boost the Company's gross margin and profit, it said. In addition, the current recipe for success should be applied to new areas. On this basis, GBC expects a profitable growth phase to begin in fiscal 2021, with revenue growth of 20% over the next two fiscal years. As a result, revenue would increase from AUD 15.20 million in 2020 to AUD 29.51 million in 2023. With this expected strong revenue momentum and economies of scale developing, gross margin should increase to 60%. EBITDA would then climb from AUD 3.03 million in 2020 to AUD 8.86 million. Based on the DCF model, GBC has published a price target of AUD 0.09 (EUR 0.06) for Aspermont shares. The price potential is thus considerable.

HelloFresh: Analysts lower their thumbs

The outlook for HelloFresh is less optimistic. At least, this is the opinion of the analysts at Bernstein Research, the HelloFresh share with "Underperform". The price target is EUR 51.50, well below the current level of around EUR 90. Analyst William Woods evaluated the past quarterly figures and the customer structure of the cooking box provider. His conclusion: the quality of the customer base is weak and characterized by high churn. He believes that the new DAX member will have a hard time meeting the high expectations. The cooking box provider itself expects significant growth in the coming years. To achieve this, however, it currently has to invest and expand capacity. That comes at the expense of margins. In the second quarter of the current year, this was not yet noticeable. In the three-month period, HelloFresh generated sales of around EUR 1.55 billion (Q2 2020: EUR 972 million), slightly more than analysts expected on average. Adjusted EBITDA was slightly above analysts' estimates of EUR 155 million at EUR 158 million (Q2 2020: EUR 154 million). For the full year 2021, the Company has raised its revenue forecast from 35-45% to 45-55%. Due to the accelerated expansion of production capacities, fulfillment costs in the current year are expected to be higher than initially assumed. Accordingly, the adjusted EBITDA margin for the full year 2021 is likely to be between 8.25% and 10.25%. Originally, 10% to 12% had been planned.

MorphoSys: No sign of a rebound

Investors are waiting in vain for a rebound at MorphoSys. Product sales of the cancer drug Monjuvi are below expectations, and the billion-dollar acquisition of Constellation Pharmaceuticals is weighing on the stock. As a result, the share has developed a clear downward trend in recent months. But even at the current level, Goldman Sachs, for example, sees no upside potential.

The US investment bank has reinstated MorphoSys in its coverage. The share is currently only rated as "Neutral". The price target of EUR 42 is only at the current level. The acquisition of Constellation Pharmaceuticals would strengthen MorphoSys's previously thin research pipeline, provide medium- and long-term sales potential, and reduce the dependence on the hopeful Monjuvi. However, the high acquisition costs would further delay the achievement of profitability.

Investors need to be patient with MorphoSys. HelloFresh has performed very well, and as Bernstein's study shows, the potential for a setback is high. If Aspermont stays in the trend channel, 20% to 30% price gains are possible, perhaps more in the long term.


Fabian Lorenz

For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

About the author

Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.

Related comments:

16. September 2021 | 11:58 CET | by André Will-Laudien

Siemens Healthineers, PuriflOH, Fresenius, Novavax - Focusing on health!

  • Investments

The pandemic outbreak in 2020 ushered in a new era. People's health is once again moving to the center of attention. Politicians worldwide see themselves obligated to make public life safe, but whether this will be 100% successful remains questionable. Ultimately, it will depend on the commitment of private companies to what extent the existing health issues can be solved and by what means. On the capital markets, the healthcare sector has been sailing on the highest wave for months because the dangers for billions of people need to be reduced, and framework conditions for public life need to be created. Who benefits the most?


10. September 2021 | 11:16 CET | by Stefan Feulner

GameStop, wallstreet:online, Nikola - It goes on blithely

  • Investments

The ECB is following the lead of the FED. Although some council members warned not to ignore the risk of too high inflation, an end to the ultra-loose monetary policy is not in sight. Only the purchase of government and corporate securities under the Corona emergency purchase program should be "moderately" lower in the fourth quarter. The pro-growth decision is a balm for the stock markets. New highs should follow after the last mini-corrections.


09. September 2021 | 12:08 CET | by Nico Popp

SMA Solar, Memiontec, CureVac: Doing good and earning money

  • Investments

When young founders develop business models, it is often a question of "purpose," i.e. the best possible (good) purpose of a company. For the new generation, money is no longer the only thing that counts. Instead, earning money and doing good are the watchwords. On the stock market, too, some companies make the world a little better. We look at three stocks and find out whether there is money to be made in them.